Pfizer Receives Second Request From FTC Over Hospira Deal
14 Maio 2015 - 2:13PM
Dow Jones News
By Chelsey Dulaney
Pfizer Inc. said Thursday that the U.S. Federal Trade Commission
has requested additional information about its proposed acquisition
of Hospira Inc.
Pfizer said the second request was an anticipated part of the
regulatory approval process. The company said it continues to
expect the deal to close in the second half of the year.
Pfizer struck a deal to buy Hospira in February for about $16
billion in cash.
Hospira is among the leading companies selling injectable drugs
and biosimilars.
The deal would give Pfizer, which has been trying to build up
its own businesses in those areas, the opportunity to expand and
take leading positions in fast-growing markets.
Write to Chelsey Dulaney at chelsey.dulaney@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre da New York Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de Hospira Inc.